ACADIA Pharmaceuticals Inc. (ACAD): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

ACADIA Pharmaceuticals ( ACAD) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.2%. By the end of trading, ACADIA Pharmaceuticals rose $0.41 (1.7%) to $24.29 on light volume. Throughout the day, 1,307,055 shares of ACADIA Pharmaceuticals exchanged hands as compared to its average daily volume of 2,662,100 shares. The stock ranged in a price between $23.60-$24.86 after having opened the day at $23.85 as compared to the previous trading day's close of $23.88. Other companies within the Drugs industry that increased today were: Tonix Pharmaceuticals ( TNXP), up 30.1%, ARCA biopharma ( ABIO), up 25.0%, Idera Pharmaceuticals ( IDRA), up 21.9% and Bind Therapeutics ( BIND), up 14.6%.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. ACADIA Pharmaceuticals has a market cap of $2.3 billion and is part of the health care sector. Shares are up 437.6% year to date as of the close of trading on Tuesday. Currently there are 7 analysts that rate ACADIA Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates ACADIA Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share.

On the negative front, Ambit Biosciences ( AMBI), down 33.1%, Vanda Pharmaceuticals ( VNDA), down 8.2%, Pernix Therapeutics Holdings ( PTX), down 7.9% and Conatus Pharmaceuticals ( CNAT), down 6.9% , were all laggards within the drugs industry with Valeant Pharmaceuticals International ( VRX) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker